Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 May;71(5):581-8.
doi: 10.1001/jamaneurol.2014.94.

A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment

Affiliations
Randomized Controlled Trial

A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment

Balwinder Singh et al. JAMA Neurol. 2014 May.

Abstract

Importance: Previous studies suggest cross-sectional associations between a diagnosis of chronic obstructive pulmonary disease (COPD) and mild cognitive impairment (MCI). However, few studies have assessed whether COPD, a potentially modifiable factor, is associated with an increased risk for MCI and whether the relation is specific to the type of MCI.

Objective: To investigate whether a diagnosis of COPD and duration of COPD are associated with an increased risk for incident MCI and MCI subtypes (amnestic MCI [A-MCI] and nonamnestic MCI [NA-MCI]).

Design, setting, and participants: A prospective population-based cohort from the Mayo Clinic Study on Aging. We included 1425 cognitively normal individuals aged 70 to 89 years who were randomly selected from Olmsted County, Minnesota, on October 1, 2004, using the medical records linkage system. At baseline and every 15 months thereafter, participants underwent assessment with a nurse interview, neurologic examination, and neuropsychological testing. A diagnosis of COPD was confirmed via medical record review. A baseline diagnosis of COPD and duration of COPD were examined as risk factors for MCI and MCI subtypes using Cox proportional hazards models and adjusting for demographic variables and medical comorbidities, with age as the time scale.

Exposure: A baseline diagnosis of COPD and duration of COPD.

Main outcomes and measures: Incident MCI, A-MCI, and NA-MCI.

Results: Of the 1425 participants with normal cognition at baseline, 370 developed incident MCI. The median duration of follow-up was 5.1 years (interquartile range, 3.8-5.4 years). A diagnosis of COPD significantly increased the risk for NA-MCI by 83% (hazard ratio, 1.83 [95% CI, 1.04-3.23]), but not of any MCI or A-MCI in multivariate analyses. We found a dose-response relationship such that individuals with COPD duration of longer than 5 years at baseline had the greatest risk for any MCI (hazard ratio, 1.58 [95% CI, 1.04-2.40]) and NA-MCI (2.58 [1.32-5.06]).

Conclusions and relevance: A diagnosis of COPD is associated with an increased risk for MCI, particularly NA-MCI. We have found a dose-response relationship between COPD duration and risk for MCI. These findings highlight the importance of COPD as a risk factor for MCI and may provide a substrate for early intervention to prevent or delay the onset and progression of MCI, particularly NA-MCI.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr. Mielke receives research support from the NIH/NIA and has served as a consultant for Eli Lilly. Dr. Roberts receives research support from the NIH/NIA and from Abbvie Health Economics and Outcomes Research. Dr. Scanlon has participated as an investigator in clinical trials funded by Boehringer Ingelheim, GlaxoSmithKline, Forest, Novartis and Pearl Therapeutics, and has served as a consultant to GlaxoSmithKline and Merck. Dr. Petersen serves on scientific advisory boards for Pfizer, Inc., Janssen Alzheimer Immunotherapy, Elan Pharmaceuticals, and GE Healthcare; receives royalties from the publication of Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIH/NIA. Drs. Singh, Parsaik, Geda, Pankratz, Ms. Cha, and Ms. Christianson report no disclosures.

Figures

Figure 1
Figure 1. Adjusted Kaplan-Meier plots of COPD and risk of MCI
Figure 1A shows the relationship between COPD (Yes/No) and percent-free survival of MCI. Figure 1B shows the relationship between COPD duration (>5 years vs. less) or no COPD and percent-free survival of MCI with age as the timescale.

Comment in

Similar articles

Cited by

References

    1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. - PubMed
    1. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance--United States, 1999–2011. Chest. 2013;144(1):284–305. - PMC - PubMed
    1. Li J, Huang Y, Fei GH. The evaluation of cognitive impairment and relevant factors in patients with chronic obstructive pulmonary disease. Respiration. 2013;85(2):98–105. - PubMed
    1. Grant I, Heaton RK, McSweeny AJ, Adams KM, Timms RM. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med. 1982;142(8):1470–1476. - PubMed
    1. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010;35(4):913–922. - PubMed

Publication types